**Core tip:** Serum lipase (s-Lip) is useful for diagnosing acute pancreatitis. The aim of this study was to retrospectively examine the usefulness of s-Lip for the early diagnosis of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP). Based on the eligibility and exclusion criteria, 804 cases were registered. Over the entire course, PEP occurred in 78 patients. The areas under the receiver operating characteristic curves (AUCs) were 0.908 for s-Lip (*P* \< 0.001) and 0.880 for serum amylase (s-Amy) (*P* \< 0.001), indicating both are useful for early diagnosis. By comparing the AUCs, s-Lip was found to be significantly more useful for the early diagnosis of PEP than s-Amy (*P* = 0.023).

INTRODUCTION
============

Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is new onset acute pancreatitis after ERCP. The consensus criteria and revised Atlanta criteria are international consensus diagnostic criteria\[[@B1],[@B2]\], but they are not unified or ideal in the setting of PEP\[[@B3],[@B4],[@B5]\]. In the consensus criteria, PEP is defined as \"new onset or worsened upper abdominal pain; pancreatic amylase and lipase at least three times the upper limit of normal at more than 24 h after ERCP; requiring hospital admission or a prolongation of planned admission"\[[@B1]\]. The limitations include patients in an acute pancreatitis setting or a flare-up of chronic pancreatitis that prevents PEP diagnosis in less than 24 h. In the revised Atlanta criteria, the diagnosis of PEP requires two of the following three criteria: (1) abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epigastric pain often radiating to the back); (2) serum lipase or amylase activity at least three times greater than the upper limit of normal; and (3) characteristic findings of acute pancreatitis on contrast-enhanced computed tomography (CT) and, less commonly, magnetic resonance imaging or transabdominal ultrasonography\[[@B2]\]. The limitation is the fact that it is not primarily developed to define PEP. For an assessment of the severity of PEP, it has been reported that the revised Atlanta classification is superior for predicting PEP mortality\[[@B6]\]. The frequency of PEP is reported to be 3% to 15%\[[@B7],[@B8],[@B9]\]. PEP is sometimes fatal, with death occurring in 3% of cases\[[@B7]\]. Therefore, from our experience, PEP needs to be diagnosed early so that therapeutic interventions can be carried out. Normally, acute pancreatitis is diagnosed based on elevated levels of pancreatic enzymes in the blood or urine, accompanied by abdominal pain and imaging findings\[[@B3]\]. However, using serum levels of the pancreatic enzyme amylase is problematic because of its low diagnostic specificity\[[@B10],[@B11]\]. In contrast, serum lipase (s-Lip) has been shown to be the most useful pancreatic enzyme for diagnosing acute pancreatitis, with a sensitivity of 86.5%-100% and specificity of 84.7%-99.0%\[[@B11]\]. Moreover, s-Lip is known to have greater diagnostic power than serum amylase (s-Amy)\[[@B12],[@B13]\]. Furthermore, s-Lip levels increase in the early stages of acute pancreatitis and have been reported to be useful for diagnosing acute pancreatitis when s-Amy levels are normal\[[@B13],[@B14]\]. With regard to ERCP, although there have been reports on how s-Lip and other pancreatic enzyme levels change over time\[[@B15],[@B16]\], the usefulness of s-Lip for the early diagnosis of PEP has yet to be fully investigated.

Thus, we conducted a retrospective study to examine the usefulness of s-Lip and s-Amy for the early diagnosis of PEP.

MATERIALS AND METHODS
=====================

Patients
--------

A total of 4192 patients who underwent ERCP at Kitasato University Hospital and Kitasato University East Hospital over a 5-year period from October 1, 2012 to September 30, 2017 were evaluated for inclusion. The eligibility criteria included having had (1) Both s-Lip and s-Amy measured before ERCP, 3 h post-ERCP, and the next morning; (2) Naïve major duodenal papilla; and (3) Continuous follow-up after ERCP. The exclusion criteria included acute pancreatitis, history of chronic pancreatitis, cholangiojejunostomy for pancreatic disease, and kidney dysfunction with an estimated glomerular filtration rate ≤ 44 mL/min. We excluded cases diagnosed as acute or chronic pancreatitis by imaging.

Methods
-------

Our study was reviewed and approved by our institutional ethics committee. Data on the purpose of ERCP, content of examinations, and post-ERCP course were collected from an ERCP database and from the medical records of the Department of Gastroenterology, Kitasato University School of Medicine. Assessments of physical findings, blood test items, and, if necessary, imaging findings that would indicate PEP were conducted 3 h after ERCP and the following morning. The primary outcomes were a comparison of the areas under the receiver operating characteristic (ROC) curves (AUCs) of s-Lip and s-Amy, s-Lip and s-Amy cutoff values based on the presence or absence of PEP in the early stage after ERCP *via* ROC curves, and comparisons of the diagnostic properties \[sensitivities, specificities, positive predictive values (PPV), and negative predictive value (NPV)\] of these cutoff values for PEP diagnosis.

Naïve major duodenal papilla was defined as duodenal papilla that had not been treated. Diagnostic ERCP was defined as cholangiography and/or pancreatography, bile cytology and/or pancreatic juice cytology, or intraductal ultrasonography. Therapeutic ERCP was defined as therapeutic interventions that did not include any form of diagnostic ERCP.

Serum pancreatic enzymes were considered elevated when the upper bounds of our institution's reference values exceeded (s-Lip 55 U/L and s-Amy 132 U/L) and the following PEP diagnostic criteria were not met: (1) Acute episodes of abdominal pain and pressure pain on the upper abdomen; (2) Elevated levels of pancreatic enzymes in the blood or urine; and (3) Abnormal signs of acute pancreatitis by abdominal ultrasonography, CT, or magnetic resonance imaging. PEP was diagnosed when at least 2 of these 3 items were met and the presence of other pancreatic diseases or acute abdomen could be excluded\[[@B3]\]. For example, in elderly people, it is often difficult to evaluate the presence or absence of spontaneous pain due to the effects of analgesics used in ERCP. Thus, if hyperlipasemia or hyperamylasemia occurred after ERCP, an imaging test was added at the discretion of the attending physician. Therefore, even if the abdominal pain was mild, it was determined as PEP if pancreatitis was observed in the image findings. Up to 3 h post-ERCP was analyzed as the early stage after ERCP, and from 3 h post-ERCP to the next morning was analyzed as the late stage after ERCP. An early PEP diagnosis was defined as one made in the early stage after ERCP. Patients diagnosed with PEP in the early stage are not included among patients diagnosed with PEP in the late stage after ERCP. PEP severity was assessed using the grades of severity according to the revised Atlanta criteria\[[@B2]\].

Statistical analysis
--------------------

ROC curves were constructed to establish relationships between sensitivity and specificity. ROC analysis was performed using the statistical package SPSS Base 17.0 (IBM Corp., Armonk, NY, United States). Analysis of s-Lip and s-Amy AUCs and cutoff values based on the presence or absence of PEP was performed using SPSS Base 17.0 (IBM Corp., Armonk, NY, United States). The DeLong test was used to perform head-to-head comparison between s-Lip and s-Amy for diagnosing PEP. Cutoff values were the closest point from the upper left of the ROC curves. Continuous data were given as the median and range. Categorical data were shown as number and percentages. *P* values \< 0.05 indicated statistical significance.

RESULTS
=======

Based on the eligibility and exclusion criteria, 804 cases were registered (Figure [1](#F1){ref-type="fig"}). The patients' median age was 71 years (range, 6-98 years) (male, 496, 61.7%); 31 (3.9%) had a history of pancreatitis, 6 (0.75%) had a history of PEP, 3 (0.4%) displayed sphincter Oddi dysfunction, 412 (51.2%) had benign disease, 303 (37.7%) underwent diagnostic ERCP, 202 (25.1%) had hyperlipasemia before ERCP, and 97 (12.1%) had hyperamylasemia before ERCP (Table [1](#T1){ref-type="table"}).

###### 

Participant background

  **Characteristic**                 **Value median \[range\] or *n* (%)**
  ---------------------------------- ---------------------------------------
  Age, yr                            71 \[6-98\]
  Sex                                
  Male                               496 (61.7)
  Female                             308 (38.3)
  History of previous pancreatitis   
  Yes                                31 (3.9)
  No                                 773 (96.1)
  History of previous PEP            
  Yes                                6 (0.7)
  No                                 798 (99.3)
  Sphincter of Oddi dysfunction      
  Yes                                3 (0.4)
  No                                 801 (99.6)
  Diagnosis                          
  Benign                             412 (51.2)
  Malignancy                         392 (48.8)
  Indications for ERCP               
  Diagnostic                         303 (37.7)
  Therapeutic                        501 (62.3)
  Hyperlipasemia before ERCP         
  Yes                                202 (25.1)
  No                                 602 (74.9)
  Hyperamylasemia before ERCP        
  Yes                                97 (12.1)
  No                                 707 (87.9)

ERCP: Endoscopic retrograde cholangiopancreatography; PEP: Post-endoscopic retrograde cholangiopancreatography pancreatitis.

![Flowchart for case extraction of naïve major duodenal papilla from the full population of 4192 cases.](WJGE-11-477-g001){#F1}

Of the patients with serum pancreatic enzyme levels greater than 3 times the institutional upper bound after ERCP, in the early stage after ERCP, 236 patients (29.4%) exhibited hyperlipasemia and 104 patients (12.9%) exhibited hyperamylasemia. In the late stage after ERCP, 239 patients (29.7%) exhibited hyperlipasemia and 138 patients (17.2%) exhibited hyperamylasemia. Over the entire course, PEP occurred in 78 patients (9.7%). It occurred in the early stage after ERCP in 40 patients (51.3%) and in the late stage after ERCP in 38 patients (48.7%) (Table [2](#T2){ref-type="table"}). Based on the grades of severity by the revised Atlanta criteria\[[@B2]\], there were 72 mild PEP cases (9.0%), 5 moderate cases (0.6%), and 1 severe case (0.1%) (Table [3](#T3){ref-type="table"}).

###### 

Incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis and elevated serum pancreatic enzyme levels in the early and late stages after endoscopic retrograde cholangiopancreatography, *n* (%)

                                                    **Early stage after ERCP[1](#T2FN1){ref-type="table-fn"}**   **Late stage after ERCP[2](#T2FN2){ref-type="table-fn"}**
  ------------------------------------------------- ------------------------------------------------------------ -----------------------------------------------------------
  PEP                                                                                                            
  Yes                                               40 (5.0)                                                     38 (4.7)
  No                                                764 (95.0)                                                   766 (95.3)
  Hyperlipasemia[3](#T2FN3){ref-type="table-fn"}                                                                 
  Yes                                               236 (29.4)                                                   239 (29.7)
  No                                                568 (70.6)                                                   565 (70.3)
  Hyperamylasemia[3](#T2FN3){ref-type="table-fn"}                                                                
  Yes                                               104 (12.9)                                                   138 (17.2)
  No                                                700 (87.1)                                                   666 (82.8)

Early stage is within 3 h after ERCP.

Late stage is from 3 h after ERCP to the next morning.

More than 3 times the standard value for the facility. ERCP: Endoscopic retrograde cholangiopancreatography; PEP: Post-endoscopic retrograde cholangiopancreatography pancreatitis.

###### 

Incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis among participants^1^, *n* (%)

             **Value**
  ---------- -----------
  PEP        78 (9.7)
  Mild       72 (9.0)
  Moderate   5 (0.6)
  Severe     1 (0.1)

^1^Acute pancreatitis classification from the revised Atlanta classification\[[@B2]\]. PEP: Post-endoscopic retrograde cholangiopancreatography pancreatitis.

Figure [2](#F2){ref-type="fig"} shows the ROC curves for s-Lip and s-Amy based on the presence or absence of PEP onset in the early stage after ERCP. The AUCs were 0.908 for s-Lip \[95% confidence interval (CI): 0.880-0.940, *P* \< 0.001\] and 0.880 for s-Amy (95%CI: 0.846-0.915, *P* \< 0.001), indicating both are useful for early diagnosis. By comparing the AUCs, s-Lip was found to be significantly more useful for the early diagnosis of PEP than s-Amy (*P* = 0.023) (Table [4](#T4){ref-type="table"}). The optimal cutoff values calculated from the ROC curves were 342 U/L for s-Lip (sensitivity, 0.859; specificity, 0.867; PPV, 0.405; NPV, 0.981) and 171 U/L for s-Amy (sensitivity, 0.859; specificity, 0.763; PPV, 0.277; NPV, 0.979).

![Receiver operating characteristic curves calculated using post-endoscopic retrograde cholangiopancreatography pancreatitis s-Lipase and s-Amylase levels at 3 h after endoscopic retrograde cholangiopancreatography. The areas under the receiver operating characteristic curves were 0.908 for s-Lip (95%CI: 0.880-0.940, *P* \< 0.001) and 0.880 for s-Amy (95%CI: 0.846-0.915, *P* \< 0.001).](WJGE-11-477-g002){#F2}

###### 

The areas under the receiver operating characteristic curves and optimal cutoff values for s-Lipase and s-Amylase based on the presence/absence of post-endoscopic retrograde cholangiopancreatography pancreatitis in the early stage after endoscopic retrograde cholangiopancreatography

                               **s-Lip**             **s-Amy**             ***P*-value[1](#T4FN1){ref-type="table-fn"}**
  ---------------------------- --------------------- --------------------- -----------------------------------------------
  AUC (95%CI)                  0.908 (0.880-0.940)   0.880 (0.846-0.915)   0.023
  Optimal cutoff value (U/L)   342                   171                   ―
  Sensitivity                  0.859                 0.859                 ―
  Specificity                  0.867                 0.763                 ―
  Positive predictive value    0.405                 0.277                 ―
  Negative predictive value    0.981                 0.979                 ―

*P* \< 0.05, s-Lip *vs* s-Amy. AUC: Area under the curve; CI: Confidence interval; s-Lip, Serum lipase; s-Amy: Serum amylase.

DISCUSSION
==========

The objective of this study was to examine the usefulness of s-Lip for the early diagnosis of PEP, including a comparison with s-Amy. Our study indicated that s-Lip might be preferable for the early diagnosis of PEP (ROC analysis, *P* = 0.023).

ERCP is now an important examination method in the diagnosis and treatment of pancreaticobiliary diseases. Therefore, although it is important to develop methods for preventing PEP, it is also necessary to discover other indicators so that when PEP cannot be avoided, it can be diagnosed and treated early. As with acute pancreatitis, if PEP is diagnosed early, therapy appropriate for the patient's condition can be initiated early. Previous research on PEP has found that 37% of post-ERCP cases without abdominal pain but with hyperlipasemia (≥ 3 times normal upper bound) presented with PEP by CT\[[@B17]\] and that 30% of PEP cases diagnosed using image findings had pancreatic enzyme levels ≤ 3 times the normal upper bound\[[@B18]\]. However, most of these and other studies examined s-Amy levels\[[@B19]-[@B21]\]. S-Lip is superior to s-Amy in diagnosing acute pancreatitis, and if it could be shown to be similarly useful for the early diagnosis of PEP, more cases of PEP could be diagnosed early and receive treatment. The AUCs of s-Lip and s-Amy based on the presence or absence of PEP in the early stage after ERCP demonstrated the usefulness of both enzymes. Moreover, the optimal cutoff values based on the ROC curves had high sensitivity and specificity, indicating that both have high diagnostic power. The AUC of s-Lip was significantly larger, showing that s-Lip has a significantly greater diagnostic power than s-Amy for the early diagnosis of PEP. When these optimal cutoff values are used, the sensitivity of s-Lip resembles that of s-Amy. Although s-Lip and s-Amy are similarly useful for early screening tests for PEP, s-Lip had a higher specificity than s-Amy. S-Lip has a higher pancreatic specificity, and is known to be more useful than s-Amy in acute pancreatitis\[[@B12],[@B13],[@B22],[@B23]\]. S-Lip might be more useful than s-Amy for PEP, similar to acute pancreatitis. Moreover, s-Lip had a higher PPV and NPV than s-Amy. A high PPV is an advantage in the diagnosis of PEP due to the low prevalence and high fatality associated with the condition; in such cases, early diagnosis and therapeutic intervention are more important. When the s-Lip cutoff value is exceeded, it is meaningful to actively perform a contrast CT examination. Based on these results, we believe that using s-Lip, with its higher specificity and PPV, would lead to more cases of PEP being diagnosed early and receiving treatment. In fact, of the 38 patients in the present study diagnosed with PEP in the late stage after ERCP, 32 patients (84.2%) had s-Lip levels higher than our cutoff value in the early stage after ERCP. In contrast, of the 38 patients in the present study diagnosed with PEP in the late stage after ERCP, 30 patients (78.9%) had s-Amy levels higher than our cutoff value in the early stage after ERCP. Sedatives and analgesics are often administered when ERCP is performed, which can make it difficult to assess abdominal pain in the early stage after ERCP. At this stage, none of these 32 cases exhibited abdominal pain, and none of them underwent CT, abdominal ultrasonography, or other imaging examinations. If imaging had been performed to examine these cases in more detail, PEP might have been diagnosed earlier and therapeutic interventions provided in some cases. In the future, when our s-Lip cutoff value is exceeded, we will carry out an image examination even when abdominal pain is unclear, as it may be possible to diagnose PEP earlier and to perform therapeutic intervention.

This study had several limitations, the most important of which was that it was performed at two centers as a retrospective study. Moreover, too many cases were excluded according to the exclusion criteria. Therefore, the usefulness of s-Lip needs to be reexamined by prospectively registering naïve major duodenal papilla cases as part of a multicenter study. Additionally, ERCP at a high-volume center is performed on more complicated cases than at other institutions. These include patients in whom cannulation of the bile duct or pancreatic duct is difficult, such as elderly patients with underlying diseases, patients who have undergone postoperative reconstruction using a balloon enteroscope, and patients with malignant disease. Thus, there could be slight differences between populations. A multicenter study is needed to resolve this limitation.

In this study, s-Lip was more useful than s-Amy for the early diagnosis of PEP (*P* = 0.023). Using the s-Lip cutoff value calculated in this study could help to diagnose PEP earlier, so that therapeutic interventions could be provided earlier.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Serum lipase (s-Lip) is considered the most useful pancreatic enzyme for diagnosing acute pancreatitis, and s-Lip is known to have greater diagnostic power than serum amylase (s-Amy). However, its usefulness for diagnosing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) has not been sufficiently investigated.

Research motivation
-------------------

PEP is sometimes fatal. As such, PEP should be diagnosed early so that therapeutic interventions can be carried out. It is necessary to evaluate pancreatic enzymes that are useful for the early diagnosis of PEP.

Research objectives
-------------------

This study aimed to retrospectively examine the usefulness of s-Lip for the early diagnosis of PEP.

Research methods
----------------

We retrospectively examined 4192 patients who underwent ERCP at our two hospitals over the last 5 years. The primary outcomes were a comparison of the areas under the receiver operating characteristic (ROC) curves (AUCs) of s-Lip and serum amylase (s-Amy), s-Lip and s-Amy cutoff values based on the presence or absence of PEP in the early stage after ERCP *via* ROC curves, and the diagnostic properties of these cutoff values for PEP diagnosis.

Research results
----------------

In total, 804 cases were registered. The AUCs were 0.908 for s-Lip \[95% confidence interval (CI): 0.880-0.940, *P* \< 0.001\] and 0.880 for s-Amy (95%CI: 0.846-0.915, *P* \< 0.001), indicating both are useful for early diagnosis. By comparing the AUCs, s-Lip was found to be significantly more useful for the early diagnosis of PEP than s-Amy (*P* = 0.023).

Research conclusions
--------------------

S-Lip was significantly more useful for the early diagnosis of PEP. Measuring s-Lip after ERCP could help diagnose PEP early; hence, therapeutic interventions can be provided early.

Research perspectives
---------------------

Measuring s-Lip is a useful option for the early diagnosis of PEP. However, this study was limited as a retrospective at two centers. The usefulness of s-Lip needs to be reexamined by prospectively registering cases as part of a multicenter study.
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